JP2022548866A5 - - Google Patents

Info

Publication number
JP2022548866A5
JP2022548866A5 JP2022516320A JP2022516320A JP2022548866A5 JP 2022548866 A5 JP2022548866 A5 JP 2022548866A5 JP 2022516320 A JP2022516320 A JP 2022516320A JP 2022516320 A JP2022516320 A JP 2022516320A JP 2022548866 A5 JP2022548866 A5 JP 2022548866A5
Authority
JP
Japan
Prior art keywords
item
nucleic acid
recombinant nucleic
sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548866A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050503 external-priority patent/WO2021050948A1/en
Publication of JP2022548866A publication Critical patent/JP2022548866A/ja
Publication of JP2022548866A5 publication Critical patent/JP2022548866A5/ja
Pending legal-status Critical Current

Links

JP2022516320A 2019-09-12 2020-09-11 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 Pending JP2022548866A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899563P 2019-09-12 2019-09-12
US62/899,563 2019-09-12
US202062971682P 2020-02-07 2020-02-07
US62/971,682 2020-02-07
PCT/US2020/050503 WO2021050948A1 (en) 2019-09-12 2020-09-11 Compositions and methods for tcr reprogramming using fusion proteins

Publications (2)

Publication Number Publication Date
JP2022548866A JP2022548866A (ja) 2022-11-22
JP2022548866A5 true JP2022548866A5 (enExample) 2023-09-20

Family

ID=74866684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516320A Pending JP2022548866A (ja) 2019-09-12 2020-09-11 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法

Country Status (10)

Country Link
EP (1) EP4028033A4 (enExample)
JP (1) JP2022548866A (enExample)
KR (1) KR20220078607A (enExample)
CN (1) CN114828862A (enExample)
AU (1) AU2020344628A1 (enExample)
BR (1) BR112022004458A2 (enExample)
CA (1) CA3154287A1 (enExample)
IL (1) IL291236A (enExample)
MX (1) MX2022002984A (enExample)
WO (1) WO2021050948A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210104772A (ko) 2018-12-14 2021-08-25 블루버드 바이오, 인코포레이티드. 이량체화제로 조절된 면역수용체 복합체
AU2021347807A1 (en) * 2020-09-23 2023-05-04 Myeloid Therapeutics, Inc. Improved methods and compositions for expression of nucleic acids in cells
WO2023091420A2 (en) * 2021-11-16 2023-05-25 TCR2 Therapeutics Inc. Compositions and methods for t cell engineering
CN118871460A (zh) * 2022-01-07 2024-10-29 维硕公司 经工程化的PD-L1靶向γδT细胞受体
WO2024039576A2 (en) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
WO2025217063A1 (en) * 2024-04-08 2025-10-16 Baylor College Of Medicine Dual stimulatory receptors for immunotherapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
WO2011059836A2 (en) * 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
CN107858333B (zh) * 2011-10-28 2022-05-27 瑞泽恩制药公司 T细胞受体基因修饰小鼠
JP2017529841A (ja) * 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
MX2018004721A (es) * 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
WO2018067993A1 (en) * 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja) * 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
EP3548055A4 (en) * 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
JP2020513754A (ja) * 2016-12-21 2020-05-21 ティーシーアール２ セラピューティクス インク． がん治療用に操作されたｔ細胞
WO2018232020A1 (en) * 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11738047B2 (en) * 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
MX2020009371A (es) * 2018-03-09 2021-01-08 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.

Similar Documents

Publication Publication Date Title
JP2022548866A5 (enExample)
JP7179041B2 (ja) 三官能性ｔ細胞－抗原カプラ及び方法並びにこれらの使用
JP7574243B2 (ja) 抗ｃｄ７０キメラ抗原受容体
JP2021515598A5 (enExample)
JP2022531222A5 (enExample)
KR102842215B1 (ko) Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
JP7404279B2 (ja) 様々な構築物最適化を備えたｔ細胞抗原カプラ
TW201930589A (zh) 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞
JP2022501074A (ja) 血液腫瘍を治療するための遺伝子操作しているγδ−Ｔ細胞及び遺伝子操作していないγδ−Ｔ細胞に関する組成物及び方法
WO2023133357A2 (en) Engineered t cells
JP2024501831A5 (enExample)
Renner et al. RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells
WO2022150379A1 (en) Nk cell engager molecules and methods of use
KR102764613B1 (ko) NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물
Sasu et al. T cell redirecting therapies for cancer treatment
JP2026501830A (ja) 遺伝子操作ｔ細胞
JP2025539364A (ja) 遺伝子操作ｔ細胞
HK1234091B (zh) 三功能t细胞抗原偶联物及其制备方法和用途